Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 394

1.

Expression of Oestrogen Receptor, Progesterone Receptor and Akt in Canine Circumanal Gland Tumours.

Kim SH, Seung BJ, Cho SH, Lim HY, Hwang JH, Sur JH.

J Comp Pathol. 2018 Jul;162:59-65. doi: 10.1016/j.jcpa.2018.06.006. Epub 2018 Jul 18.

PMID:
30060844
2.

Hyaluronan Receptor LYVE-1-Expressing Macrophages Maintain Arterial Tone through Hyaluronan-Mediated Regulation of Smooth Muscle Cell Collagen.

Lim HY, Lim SY, Tan CK, Thiam CH, Goh CC, Carbajo D, Chew SHS, See P, Chakarov S, Wang XN, Lim LH, Johnson LA, Lum J, Fong CY, Bongso A, Biswas A, Goh C, Evrard M, Yeo KP, Basu R, Wang JK, Tan Y, Jain R, Tikoo S, Choong C, Weninger W, Poidinger M, Stanley RE, Collin M, Tan NS, Ng LG, Jackson DG, Ginhoux F, Angeli V.

Immunity. 2018 Jul 9. pii: S1074-7613(18)30290-5. doi: 10.1016/j.immuni.2018.06.008. [Epub ahead of print]

PMID:
30054204
3.

Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer.

Yu JI, Lim DH, Lee J, Kang WK, Park SH, Park JO, Park YS, Lim HY, Kim ST, Lee SJ, Kim S, Sohn TS, Lee JH, An JY, Choi MG, Bae JM, Kim HS, Ahn S.

Radiother Oncol. 2018 Jul 20. pii: S0167-8140(18)33381-4. doi: 10.1016/j.radonc.2018.07.002. [Epub ahead of print]

PMID:
30037498
4.

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.

Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, Liu XQ, Sher X, Jung H, Lee M, Lee S, Park SH, Park JO, Park YS, Lim HY, Lee H, Choi M, Talasaz A, Kang PS, Cheng J, Loboda A, Lee J, Kang WK.

Nat Med. 2018 Jul 16. doi: 10.1038/s41591-018-0101-z. [Epub ahead of print]

PMID:
30013197
5.

Effects of isometric, eccentric, or heavy slow resistance exercises on pain and function in individuals with patellar tendinopathy: A systematic review.

Lim HY, Wong SH.

Physiother Res Int. 2018 Jul 4:e1721. doi: 10.1002/pri.1721. [Epub ahead of print] Review.

PMID:
29972281
6.

Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma.

Lim HY, Merle P, Weiss KH, Yau T, Ross P, Mazzaferro V, Blanc JF, Ma YT, Yen CJ, Kocsis J, Choo SP, Sukeepaisarnjaroen W, Gérolami R, Dufour JF, Gane EJ, Ryoo BY, Peck-Radosavljevic M, Dao T, Yeo W, Lamlertthon W, Thongsawat S, Teufel M, Roth K, Reis D, Childs BH, Krissel H, Llovet JM.

Clin Cancer Res. 2018 Jun 27. doi: 10.1158/1078-0432.CCR-17-3588. [Epub ahead of print]

PMID:
29950351
7.

Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma.

Yoo C, Kang J, Lim HY, Kim JH, Lee MA, Lee KH, Kim TY, Ryoo BY.

Cancer Res Treat. 2018 Jun 13. doi: 10.4143/crt.2018.226. [Epub ahead of print]

8.

The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer.

Kim ST, Kim HK, Lee J, Park SH, Lim HY, Park YS, Kang WK, Park JO.

J Cancer. 2018 Apr 19;9(10):1791-1796. doi: 10.7150/jca.25132. eCollection 2018.

9.

Maximising yield of peripheral blood flow cytometry for chronic lymphoproliferative disorders.

Lim HY, Hong FS.

Int J Lab Hematol. 2018 May 23. doi: 10.1111/ijlh.12861. [Epub ahead of print]

PMID:
29790655
10.

Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial.

Guo J, Jin J, Oya M, Uemura H, Takahashi S, Tatsugami K, Rha SY, Lee JL, Chung J, Lim HY, Wu HC, Chang YH, Azad A, Davis ID, Carrasco-Alfonso MJ, Nanua B, Han J, Ahmad Q, Motzer R.

J Hematol Oncol. 2018 May 22;11(1):69. doi: 10.1186/s13045-018-0617-1.

11.

Potential Functional Byproducts from Guava Purée Processing.

Lim SY, Tham PY, Lim HYL, Heng WS, Chang YP.

J Food Sci. 2018 Jun;83(6):1522-1532. doi: 10.1111/1750-3841.14155. Epub 2018 May 10.

PMID:
29745989
12.

Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma.

Abou-Alfa GK, Qin S, Ryoo BY, Lu SN, Yen CJ, Feng YH, Lim HY, Izzo F, Colombo M, Sarker D, Bolondi L, Vaccaro G, Harris WP, Chen Z, Hubner RA, Meyer T, Sun W, Harding JJ, Hollywood EM, Ma J, Wan PJ, Ly M, Bomalaski J, Johnston A, Lin CC, Chao Y, Chen LT.

Ann Oncol. 2018 Jun 1;29(6):1402-1408. doi: 10.1093/annonc/mdy101.

PMID:
29659672
13.

Expanding Actin Rings Zipper the Mouse Embryo for Blastocyst Formation.

Zenker J, White MD, Gasnier M, Alvarez YD, Lim HYG, Bissiere S, Biro M, Plachta N.

Cell. 2018 Apr 19;173(3):776-791.e17. doi: 10.1016/j.cell.2018.02.035. Epub 2018 Mar 22.

PMID:
29576449
14.

c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival.

Lee SJ, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS, Kim ST.

Clin Colorectal Cancer. 2018 Mar 2. pii: S1533-0028(18)30004-5. doi: 10.1016/j.clcc.2018.02.013. [Epub ahead of print]

15.

Direct Oral Anticoagulants and the Paradigm Shift in the Management of Venous Thromboembolism.

Lim HY, Nandurkar H, Ho P.

Semin Thromb Hemost. 2018 Apr;44(3):261-266. doi: 10.1055/s-0038-1637750. Epub 2018 Mar 20.

PMID:
29558778
16.

Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer.

Lee J, Kim ST, Park S, Lee S, Park SH, Park JO, Lim HY, Ahn H, Bok H, Kim KM, Ahn MJ, Kang WK, Park YS.

Clin Colorectal Cancer. 2018 Jun;17(2):140-146. doi: 10.1016/j.clcc.2018.01.005. Epub 2018 Jan 31.

PMID:
29551559
17.

An evaluation of global coagulation assays in myeloproliferative neoplasm.

Lim HY, Ng C, Rigano J, Tacey M, Donnan G, Nandurkar H, Ho P.

Blood Coagul Fibrinolysis. 2018 Apr;29(3):300-306. doi: 10.1097/MBC.0000000000000724.

PMID:
29538005
18.

The cryptochrome inhibitor KS15 enhances E-box-mediated transcription by disrupting the feedback action of a circadian transcription-repressor complex.

Jang J, Chung S, Choi Y, Lim HY, Son Y, Chun SK, Son GH, Kim K, Suh YG, Jung JW.

Life Sci. 2018 May 1;200:49-55. doi: 10.1016/j.lfs.2018.03.022. Epub 2018 Mar 10.

PMID:
29534992
19.

Peripheral blood stem cell mobilisation with G-CSF alone versus G-CSF and cyclophosphamide after bortezomib, cyclophosphamide and dexamethasone induction in multiple myeloma.

Chua CC, Lim HY, Chai KL, Ong J, Sim S, Wood C, Dickinson M, Campbell P, Hempton J, King H, Dowsing C, Bergin K, Muir S, Gibbs S, Grigg A.

Bone Marrow Transplant. 2018 Mar 9. doi: 10.1038/s41409-018-0152-2. [Epub ahead of print]

PMID:
29523889
20.

The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer.

Lee SJ, Kim JE, Kim ST, Lee J, Park SH, Park JO, Kang WK, Park YS, Lim HY.

Transl Oncol. 2018 Apr;11(2):353-357. doi: 10.1016/j.tranon.2018.01.007. Epub 2018 Feb 20.

21.

A point-of-care diagnostic system to influenza viruses using chip-based ultra-fast PCR.

Kwon SH, Lee S, Jang J, Seo Y, Lim HY.

J Med Virol. 2018 Jun;90(6):1019-1026. doi: 10.1002/jmv.25046. Epub 2018 Feb 27.

PMID:
29424457
22.

Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients.

Kim ST, Banks KC, Pectasides E, Kim SY, Kim K, Lanman RB, Talasaz A, An J, Choi MG, Lee JH, Sohn TS, Bae JM, Kim S, Park SH, Park JO, Park YS, Lim HY, Kim NKD, Park W, Lee H, Bass AJ, Kim K, Kang WK, Lee J.

Ann Oncol. 2018 Apr 1;29(4):1037-1048. doi: 10.1093/annonc/mdy034.

23.

CD204-Expressing Tumor-Associated Macrophages Are Associated With Malignant, High-Grade, and Hormone Receptor-Negative Canine Mammary Gland Tumors.

Seung BJ, Lim HY, Shin JI, Kim HW, Cho SH, Kim SH, Sur JH.

Vet Pathol. 2018 May;55(3):417-424. doi: 10.1177/0300985817750457. Epub 2018 Jan 17.

PMID:
29343199
24.

Streptococcus Constellatus Spondylodiscitis in a Teenager: A Case Report.

Lim SW, Lim HY, Kannaiah T, Zuki Z.

Malays Orthop J. 2017 Nov;11(3):50-52. doi: 10.5704/MOJ.1711.004.

25.

Elevated CEA is associated with worse survival in recurrent rectal cancer.

Cho WK, Choi DH, Park HC, Park W, Yu JI, Park YS, Park JO, Lim HY, Kang WK, Kim HC, Cho YB, Yun SH, Lee WY.

Oncotarget. 2017 Nov 18;8(62):105936-105941. doi: 10.18632/oncotarget.22511. eCollection 2017 Dec 1.

26.

MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines.

Kim JE, Kim Y, Li G, Kim ST, Kim K, Park SH, Park JO, Park YS, Lim HY, Lee H, Sohn TS, Kim KM, Kang WK, Lee J.

Oncotarget. 2017 Nov 11;8(62):105727-105734. doi: 10.18632/oncotarget.22394. eCollection 2017 Dec 1.

27.

Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract.

Lee JY, Kim K, Sung HH, Jeon HG, Jeong BC, Seo SI, Jeon SS, Lee HM, Choi HY, Kwon GY, Kim KM, Lee J, Lim HY, Park SH.

Transl Oncol. 2018 Feb;11(1):37-42. doi: 10.1016/j.tranon.2017.10.008. Epub 2017 Nov 21.

28.

Directional associations between memory impairment and depressive symptoms: data from a longitudinal sample and meta-analysis.

Yu J, Lim HY, Abdullah FNDM, Chan HM, Mahendran R, Ho R, Kua EH, Power MJ, Feng L.

Psychol Med. 2018 Jul;48(10):1664-1672. doi: 10.1017/S0033291717003154. Epub 2017 Nov 8.

PMID:
29113607
29.

Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy.

Kim ST, Klempner SJ, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim KM, Lee J.

Oncotarget. 2017 Aug 24;8(44):77415-77423. doi: 10.18632/oncotarget.20492. eCollection 2017 Sep 29.

30.

The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs.

Kim HK, Ha SY, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS, Kim ST.

Oncotarget. 2017 May 25;8(43):73974-73980. doi: 10.18632/oncotarget.18168. eCollection 2017 Sep 26.

31.

Comparison of Five Protein Engineering Strategies for Stabilizing an α/β-Hydrolase.

Jones BJ, Lim HY, Huang J, Kazlauskas RJ.

Biochemistry. 2017 Dec 19;56(50):6521-6532. doi: 10.1021/acs.biochem.7b00571. Epub 2017 Nov 14.

PMID:
29087185
32.

The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer.

Kim ST, Lee SJ, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS.

J Cancer. 2017 Aug 23;8(14):2809-2815. doi: 10.7150/jca.18286. eCollection 2017.

33.

The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation.

Kim JS, Kim JE, Kim K, Lee J, Park JO, Lim HY, Park YS, Kang WK, Kim ST.

J Cancer. 2017 Aug 22;8(14):2713-2719. doi: 10.7150/jca.19458. eCollection 2017.

34.

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.

Motzer RJ, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, Lee JL, Melichar B, Rini BI, Choueiri TK, Zemanova M, Wood LA, Reaume MN, Stenzl A, Chowdhury S, Lim HY, McDermott R, Michael A, Bao W, Carrasco-Alfonso MJ, Aimone P, Voi M, Doehn C, Russo P, Sternberg CN; PROTECT investigators.

J Clin Oncol. 2017 Dec 10;35(35):3916-3923. doi: 10.1200/JCO.2017.73.5324. Epub 2017 Sep 13.

35.

A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer.

Kim HS, Lee JY, Lee SJ, Lim HY, Sung HH, Jeon HG, Jeong BC, Seo SI, Jeon SS, Lee HM, Choi HY, Park SH.

BMC Urol. 2017 Aug 22;17(1):63. doi: 10.1186/s12894-017-0253-z.

36.

MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines.

Kim JE, Kim KK, Kim SY, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim ST.

J Cancer. 2017 Jul 20;8(12):2263-2268. doi: 10.7150/jca.19582. eCollection 2017.

37.

Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials.

Kim ST, Kim KM, Kim NKD, Park JO, Ahn S, Yun JW, Kim KT, Park SH, Park PJ, Kim HC, Sohn TS, Choi DI, Cho JH, Heo JS, Kwon W, Lee H, Min BH, Hong SN, Park YS, Lim HY, Kang WK, Park WY, Lee J.

Oncologist. 2017 Oct;22(10):1169-1177. doi: 10.1634/theoncologist.2017-0020. Epub 2017 Jul 12.

PMID:
28701572
38.

Discovery of a Benzamide Derivative That Protects Pancreatic β-Cells against Endoplasmic Reticulum Stress.

Duan H, Li Y, Arora D, Xu D, Lim HY, Wang W.

J Med Chem. 2017 Jul 27;60(14):6191-6204. doi: 10.1021/acs.jmedchem.7b00435. Epub 2017 Jul 11.

39.

Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer.

Jung KS, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim ST.

Mol Clin Oncol. 2017 Jul;7(1):27-31. doi: 10.3892/mco.2017.1272. Epub 2017 May 29.

40.

The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC).

Heo MH, Kim HK, Lee H, Kim KM, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS, Kim ST.

J Cancer. 2017 May 12;8(8):1395-1399. doi: 10.7150/jca.17898. eCollection 2017.

41.

Venous thromboembolism management in Northeast Melbourne: how does it compare to international guidelines and data?

Lim HY, Chua CC, Tacey M, Sleeman M, Donnan G, Nandurkar H, Ho P.

Intern Med J. 2017 Sep;47(9):1034-1042. doi: 10.1111/imj.13525.

PMID:
28635085
42.

Cell Death-Associated Ribosomal RNA Cleavage in Postmortem Tissues and Its Forensic Applications.

Kim JY, Kim Y, Cha HK, Lim HY, Kim H, Chung S, Hwang JJ, Park SH, Son GH.

Mol Cells. 2017 Jun 30;40(6):410-417. doi: 10.14348/molcells.2017.0039. Epub 2017 Jun 15.

43.

Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study.

Jung KS, Lee SJ, Park SH, Lee JL, Lee SH, Lim JY, Kang JH, Lee S, Rha SY, Lee KH, Kim HY, Lim HY.

Cancer Res Treat. 2018 Apr;50(2):488-494. doi: 10.4143/crt.2016.584. Epub 2017 May 22.

44.

Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists.

Lee SJ, Lim HY.

Expert Opin Emerg Drugs. 2017 Jun;22(2):191-200. doi: 10.1080/14728214.2017.1330886. Epub 2017 May 25. Review.

PMID:
28506080
45.

Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2-Amplified Gastric Cancer Patient-Derived Cell Model.

Jang J, Kim HK, Bang H, Kim ST, Kim SY, Park SH, Lim HY, Kang WK, Lee J, Kim KM.

Transl Oncol. 2017 Aug;10(4):469-475. doi: 10.1016/j.tranon.2017.03.001. Epub 2017 May 11.

46.

Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center's experiences.

Cho M, Ahn S, Hong M, Bang H, Van Vrancken M, Kim S, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Sun JM, Lee SH, Ahn MJ, Park K, Kim DH, Lee S, Park W, Kim KM.

Oncotarget. 2017 Jun 27;8(26):42478-42486. doi: 10.18632/oncotarget.17199.

47.

Incidence and risk factors for rectal pain after laparoscopic rectal cancer surgery.

Lee JY, Kim HC, Huh JW, Sim WS, Lim HY, Lee EK, Park HG, Bang YJ.

J Int Med Res. 2017 Apr;45(2):781-791. doi: 10.1177/0300060517693421. Epub 2017 Mar 16.

48.

Re-visiting the tympanic membrane vicinity as core body temperature measurement site.

Yeoh WK, Lee JKW, Lim HY, Gan CW, Liang W, Tan KK.

PLoS One. 2017 Apr 17;12(4):e0174120. doi: 10.1371/journal.pone.0174120. eCollection 2017. Review.

49.

Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors.

Lee SJ, Lee SY, Lee WS, Yoo JS, Sun JM, Lee J, Park SH, Park JO, Ahn MJ, Lim HY, Kang WK, Park YS.

Invest New Drugs. 2017 Dec;35(6):782-790. doi: 10.1007/s10637-017-0463-y. Epub 2017 Apr 8.

50.

An investigation of the role of gene copy number variations in sorafenib sensitivity in metastatic hepatocellular carcinoma patients.

Lee JY, Hong M, Lee J, Lee S, Kim KM, Park C, Lim HY.

J Cancer. 2017 Feb 25;8(5):730-736. doi: 10.7150/jca.17887. eCollection 2017.

Supplemental Content

Loading ...
Support Center